Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Moberg Pharma announced that a grant of EUR0.9m in public funding has been approved by Eurostars for a project proposal related to late-stage development of Moberg Pharma’s BUPI project.
Subscribe to our email newsletter
The Eurostars project "BUPI – a long-acting lozenge with bupivacaine for pain relief of Oral Mucositis in cancer patients" will be managed by Moberg Pharma and includes six external partners in Sweden and Denmark: Oracain ApS, TFS Trial Form Support ApS, Aarhus University Hospital, University Hospital Herlev, PCG Clinical Services AB and Skåne University Hospital.
The funding from Eurostars will co-finance late-stage development of the product including a clinical phase III study.
Eurostars is a joint programme between EUREKA and the European Commission, co-funded from the national budgets of 34 Eurostars Participating States and Partner Countries and by the European Union through Horizon 2020. Eurostars supports international innovative projects led by R&D-performing small- and medium-sized enterprises.
"We are delighted to receive the Eurostars grant in strong competition with many other applications across Europe. The grant supports our efforts to provide a longer and more effective pain relief to cancer patients suffering from Oral Mucositis. We expect to report topline results from the ongoing phase II study on BUPI later this year," said Peter Wolpert, CEO of Moberg Pharma AB.